1UK Prospective Diabetes Study(UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes[J]. Lancet , 1998, 352 : 837-853.
2Turner RC, Cull CA, Frighi V, et al . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies(UKPDS 49)[J]. JAMA ,1999,281:2005-2012.
3Saudek CD: Novel forms of insulin delivery[J]. Endocrinol Metab Clin North Am,1997,26:599-610.
4Cefalu WT. Novel routes of insulin delivery for patients with type 1 or type 2 Diabetes[J], Ann Med ,2001 ,33:579-586.
5Hilsted J, Madsbad S, Hviderg A, et al . Intranasal insulin therapy: the clinical realitiesk[J]. Diabetologia , 1995, 38:680-684.
6Coates PA, Ismail IS, Luzio SD, et al . Intranasal insulin:the effects of three dose regimens on postprandial glycemic profiles in type 2 diabetic profiles[J]. Diabet Med , 1995, 12:235-239.
7Sayani AP, Chien Yw. Systemic delivery of peptides and proteins across absorptive mucosae[J]. Crit Rev Ther drug Carrier Syst , 1996,13:85-184.
8Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin[J]. Diabetic Med, 1997, 14 : 63-72.
9Heise T, Rave K, Bott S, et al . Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin[J]. Diahetes , 2000,49(Suppl 1 ) : A10.
10Laube BL, Benedict GW, Dobs AS. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with non-insulin dependent diabetes mellitus[J]. J Aerosol Med , 1998,11:153-173.
